ロード中...
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model
PURPOSE: The prognosis for patients diagnosed with glioblastoma multiforme (GBM) remains dismal, with current treatment prolonging survival only modestly. As such, there remains a strong need for novel therapeutic strategies. The janus kinase (JAK)2/signal transducer and activator of transcription (...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5734728/ https://ncbi.nlm.nih.gov/pubmed/29253028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0189670 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|